Washington, DC, February 22, 2010 – The American Association for Clinical Chemistry (AACC) announces the signing of a memorandum of understanding (MOU) with the National Cancer Institute’s Clinical Proteomics Technologies for Cancer (CPTC) regarding potential collaborations for educating the clinical laboratory community in the area of proteomics standards and technology advances. The MOU was signed on behalf of AACC by Barbara Goldsmith, PhD, 2009 AACC President.
Proteomics is the field of study encompassing the identification and quantification of proteins. This includes the effect of their modifications, interactions, activities, and function in cancer and other disease states, as well as during treatment. AACC looks forward to assisting CPTC in their ongoing efforts to link laboratory professionals with biologists and clinicians to accelerate the development, optimization and standardization of proteomic technologies for the detection of cancer-relevant proteins/peptides in clinical specimens.
With this MOU, AACC and CPTC have created a framework for pursuing collaborations in the development of educational events and workshops to improve the scientific community’s awareness of research in clinical proteomics and the need for proteomic standards, best practices, community reagents, and data policies.
For more information about AACC, proteomics, or the MOU, please contact Peter Patterson or either of the above referenced phone numbers.